Similar articles

• [Pharmacokinetics and drug interactions of antidepressive agents].

  Sawada Y, Ohtani H. Sawada Y, et al. Nihon Rinsho. 2001 Aug;59(8):1539-45. Nihon Rinsho. 2001. PMID: 11519155 Review. Japanese.
• Pharmacokinetics of milnacipran in comparison with other antidepressants.

  Puozzo C, Leonard BE. Puozzo C, et al. Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:15-27. doi: 10.1097/00004850-199609004-00003. Int Clin Psychopharmacol. 1996. PMID: 8923123 Review.
• Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.

  Caccia S. Caccia S. Clin Pharmacokinet. 1998 Apr;34(4):281-302. doi: 10.2165/00003088-199834040-00002. Clin Pharmacokinet. 1998. PMID: 9571301 Review.
• Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.

  Kuhn UD, Kirsch M, Merkel U, Eberhardt AM, Wenda B, Maurer I, Härtter S, Hiemke C, Volz HP, Balogh A. Kuhn UD, et al. Int J Clin Pharmacol Ther. 2007 Jan;45(1):36-46. doi: 10.5414/cpp45036. Int J Clin Pharmacol Ther. 2007. PMID: 17256449 Clinical Trial.
• Pharmacology and pharmacokinetics of milnacipran.

  Puozzo C, Panconi E, Deprez D. Puozzo C, et al. Int Clin Psychopharmacol. 2002 Jun;17 Suppl 1:S25-35. doi: 10.1097/00004850-200206001-00004. Int Clin Psychopharmacol. 2002. PMID: 12369608 Review.